Document is current
Any future updates will be listed below
-
Authors
Hovestadt, Volker
Smith, Kyle S.
Bihannic, Laure
Filbin, Mariella G.
Shaw, McKenzie L.
Baumgartner, Alicia
DeWitt, John C.
Groves, Andrew
Mayr, Lisa
Weisman, Hannah R.
Richman, Alyssa R.
Shore, Marni E.
Goumnerova, Liliana
Rosencrance, Celeste
Carter, Robert A.
Phoenix, Timothy N.
Hadley, Jennifer L.
Tong, Yiai
Houston, Jim
Ashmun, Richard A.
DeCuypere, Michael
Sharma, Tanvi
Flasch, Diane
Silkov, Antonina
Ligon, Keith L.
Pomeroy, Scott L.
Rivera, Miguel N.
Rozenblatt-Rosen, Orit
Rusert, Jessica M.
Wechsler-Reya, Robert J.
Li, Xiao-Nan
Peyrl, Andreas
Gojo, Johannes
Kirchhofer, Dominik
Lötsch, Daniela
Czech, Thomas
Dorfer, Christian
Haberler, Christine
Geyeregger, Rene
Halfmann, Angela
Gawad, Charles
Easton, John
Pfister, Stefan M.
Regev, Aviv
Gajjar, Amar
Orr, Brent A.
Slavc, Irene
Robinson, Giles W.
Bernstein, Bradley E.
Suvà, Mario L.
Northcott, Paul A.
- License Information
-
More Information
Article History
Received: 13 September 2018
Accepted: 21 June 2019
First Online: 24 July 2019
Competing interests
: B.E.B. discloses financial interests in Fulcrum Therapeutics, 1CellBio, HiFiBio, Arsenal Biosciences, Cell Signaling Technologies and Nohla Therapeutics. A.R. is a founder and equity holder of Celsius Therapeutics and an SAB member of ThermoFisher Scientific and Syros Pharmaceuticals.
